.Wei Wang

Dr. .Wei Wang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
XGXiu Li Guo
Xiu Li Guo
JWJian Wen Wang
Jian Wen Wang
MTMei Tu
Mei Tu
.W.Wei Wang
.Wei Wang
Objective: Emerging evidence highlighted that perirenal adipose tissue might regulate the cardiovascular and metabolism system through several pathways. This study aimed to assess the association between perirenal fat thickness (PrFT) and subclinical carotid atherosclerosis (SCCA) in type 2 diabetes mellitus (T2DM).Method: A total of 670 participants with complete data were included in this study. The trained reviewer collected demographic and anthropometric information. Laboratory assessments were determined by standard methods. PrFT and SCCA were evaluated by computed tomography and ultrasound. Binomial logistic regression analysis was conducted to assess the association between PrFT and SCCA. Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the identifying value of PrFT for SCCA.Results: Overall, the prevalence of SCCA was 61.8% in T2DM. PrFT was significantly increased in the SCCA group. Growing trends were observed in the prevalence of hypertension, carotid intima-media thickness (cIMT) > 1, plaque, and SCCA across the PrFT quartiles. Spearman correlation analysis revealed that PrFT was positively associated with cIMT (r = 0.401, p < 0.001). This correlation remained significant after adjustment for visceral fat area (VFA), subcutaneous fat area (SFA), and traditional metabolic risk factors (β = 0.184, p < 0.001). Meanwhile, PrFT was independently correlated with plaque, cIMT > 1 mm, and SCCA. The ORs (95% CI) were 1.072 (1.014–1.135), 1.319 (1.195–1.455), and 1.216 (1.119–1.322). Furthermore, PrFT remained correlated considerably with SCCA in subgroup analysis after stratification for age, sex, smoking, hypertension, and body mass index. From the ROC curve analysis, the AUCs (95% CI) of PrFT, VFA, and SFA identifying SCCA were 0.794 (0.760–0.828), 0.760 (0.724–0.796), and 0.697 (0.656–0.737), respectively. The AUC of PrFT was significantly higher than VFA (p = 0.028) and SFA (p < 0.001). The optimal cutoff values of PrFT were 14.0 mm, with a sensitivity of 66.7% and a specificity of 76.2%.Conclusion: PrFT was independently associated with cIMT, plaque, cIMT > 1 mm, and SCCA as a superior obesity-related marker of SCCA in T2DM.Clinical trial registration: Clinical Trials.Gov, identifier ChiCTR2100052032.

6 April 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YTYan Tong
Yan Tong
JHJian Qing Huang
Jian Qing Huang
YCYang Chen
Yang Chen
MTMei Tu
Mei Tu
.W.Wei Wang
.Wei Wang
Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) profoundly affect the gastrointestinal motor system, which may increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms. Hence, this observational study mainly aimed to assess the influence of GLP-1 RAs liraglutide and DPP-4i sitagliptin on bowel preparation in type 2 diabetes (T2DM).Method: This observational study consecutively enrolled T2DM scheduled for a colonoscopy. Participants were prospectively separated into the liraglutide group (n = 120), sitagliptin group (n = 120), and control group (n = 120) based on the current hypoglycemic regimen. 3L split-dose polyethylene glycol regimens were used for bowel preparation. Experienced gastrointestinal endoscopists conducted colonoscopies. Lawrance Bowel-Preparation Tolerability Questionnaire and Boston Bowel Preparation Scale (BBPS) were conducted to assess bowel cleaning quality, tolerability, and safety.Results: The incidence of inadequate bowel cleaning was 17.5% in the liraglutide group, 20.5% in the sitagliptin group, and 21.7% in the control group. The difference among the three groups was not statistically significant (p = 0.927). Meanwhile, there were no significant differences in the mean BBPS, cecal intubation time, and polyp-detecting rates among the three groups (all p > 0.0.05). Nausea, vomiting, and bloating scores were increased in the liraglutide group compared with the other two groups (p < 0.05), whereas most were mild or very mild. Subgroup analyses showed that the incidence of inadequate bowel cleaning in T2DM with diabetic peripheral neuropathy (DPN) was increased in the liraglutide group compared with the sitagliptin group (61.3% vs. 32.1%, p = 0.022) and control group (61.3% vs. 32.8%, p = 0.025).Conclusion: GLP-1RA liraglutide or DPP-4i sitagliptin did not significantly increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms during bowel preparation. Liraglutide may increase the incidence of inadequate bowel preparation in patients with DPN. This study reveal that more attention and aggressive bowel preparation regimens should be given to the T2DM with DPN.Clinical Trial Registration: (https://www.chictr.org.cn/index.aspx), identifier (ChiCTR2200056148).

14 August 2019 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
WWWei Wang
Wei Wang
RWRong Dan Wu
Rong Dan Wu
.W.Wei Wang
.Wei Wang
XXXiangjin Xu
Xiangjin Xu
XSXiao Zhi Shi
Xiao Zhi Shi
WGWen Guo
Wen Guo

28 June 2023 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
JYJian Yang
Jian Yang
CLChuan Wang Li
Chuan Wang Li
JZJing Ru Zhang
Jing Ru Zhang
HQHonglin Qiu
Honglin Qiu
GXGUO XIULI
GUO XIULI
.W.Wei Wang
.Wei Wang
Objective: Recent advances in perirenal adipose tissue (PAT) highlighted that PAT might involve in the pathogenesis of chronic inflammatory and dysfunctional metabolic diseases. This study assessed the association between perirenal fat thickness (PrFT) and metabolic dysfunction-associated fatty liver disease (MALFD) in type 2 diabetes mellitus (T2DM). Methods: This study comprised 867 eligible participants with T2DM. Trained reviewers collected anthropometric and biochemical measurements. The diagnosis of MAFLD was based on the latest international expert consensus statement. PrFT and fatty liver were evaluated by computed tomography. The visceral fat area (VFA) and subcutaneous fat area (SFA) were measured by bioelectrical impedance analysis. The non-alcoholic fatty liver disease fibrosis score (NFS) and fibrosis-4 (FIB-4) index were used to assess progressive liver fibrosis in MAFLD. Results: Overall, the prevalence of MAFLD was 62.3% in T2DM. The PrFT in the MAFLD group was statistically increased than in the non-MAFLD group (P < 0.05). Correlation analysis showed that PrFT was significantly correlated with dysfunctional metabolic factors like body mass index, waist circumference, triglycerides, high-density lipoprotein cholesterol, systolic blood pressure, diastolic blood pressure, uric acid, and insulin resistance. Multiple regression analysis revealed that PrFT was positively correlated with NFS (β=0.146, P< 0.001) and FIB-4 (β=0.082, P=0.025) in the MAFLD. In contrast, PrFT was negatively correlated with CTL-S (β=− 0.188, P< 0.001). Furthermore, PrFT was also significantly associated with MAFLD independent of VFA and SFA, the OR (95% CI) was 1.279 (1.191– 1.374). Meanwhile, PrFT also had a good identifying value for MAFLD as VFA. The area under the curve (95% CI) value of PrFT identifying MAFLD was 0.782 (0.751– 0.812). The optimal cut-off value of PrFT was 12.6mm, with a sensitivity of 77.8% and specificity of 70.8%. Conclusion: PrFT was independently associated with MAFLD, NFS, and FIB-4 and showed a similar identifying value for MAFLD as VFA, which suggested that PrFT can be used as an alternative index to VFA.

1 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XGXiu Li Guo
Xiu Li Guo
MTMei Tu
Mei Tu
XQXiu Ping Qiu
Xiu Ping Qiu
.W.Wei Wang
.Wei Wang
This study aims to evaluate the relationship between perirenal adipose tissue (PAT) accumulation and the risk of lower-extremity peripheral arterial disease (LEAD) and its potential mediating role in the association between the atherogenic index of plasma (AIP) and LEAD. 828 participants with type 2 diabetes mellitus (T2DM) were included in the final analysis. Perirenal fat thickness (PrFT) was assessed using unenhanced abdominal CT to estimate PAT mass. The diagnosis of LEAD was based on the ankle-brachial index (ABI), stenosis, or occlusion in the lower limb arteries. After full adjustment for potential confounders, PrFT negatively correlated with ABI (β = − 0.265, P < 0.001) and positively correlated with AIP (β = 0.121, P < 0.001). PrFT was identified as an independent risk factor for LEAD (OR 1.14, 95% CI 1.03–1.26, P = 0.010). Restricted cubic splines analysis further revealed a non-linear association between PrFT and risk of LEAD (P for overall = 0.015; P for nonlinear = 0.039). Additionally, PrFT mediated 15.9% and 12.5% of the adverse impacts of AIP on ABI and LEAD. Furthermore, sensitivity analyses excluding 141 newly diagnosed T2DM produced consistent results. PAT accumulation was independently associated with the risk of LEAD and partially mediated the adverse impacts of AIP on ABI and LEAD.

4 June 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
XGXiu Li Guo
Xiu Li Guo
MTMei Tu
Mei Tu
XQXiu Ping Qiu
Xiu Ping Qiu
.W.Wei Wang
.Wei Wang
Background: Recent evidence suggests that the serum uric acid to apolipoprotein A1 ratio (UAR) may be a novel biomarker for metabolic dysfunction-associated steatotic liver disease (MASLD). This study aims to investigate the relationship between UAR and MASLD, and compare the diagnostic ability of UAR with other insulin resistance-related markers for MASLD in individuals with type 2 diabetes mellitus (T2DM).Method: A cohort of 1,019 individuals with T2DM was recruited from the National Metabolic Management Center of our hospital. Unenhanced abdominal CT scans were performed to evaluate liver steatosis for diagnosing MASLD. The association between UAR and the risk of MASLD was analyzed using weighted binomial logistic regression, restricted cubic splines (RCS), and subgroup analysis. Receiver operating characteristic (ROC) curve analysis was conducted to compare the diagnostic performance of UAR with other insulin resistance-related markers, including the serum uric acid to high-density lipoprotein cholesterol ratio (UHR), triglyceride to high-density lipoprotein cholesterol ratio (THR), and triglyceride to apolipoprotein A1 ratio (TAR).Results: Participants in the MASLD group exhibited elevated UAR levels. After full adjustments for potential confounders, UAR remained independently associated with MASLD (OR: 1.65, 95% CI: 1.45-1.89, P < 0.001). Subgroup analyses revealed that this association was consistent across various subgroups, including sex, drinking status, hypertension, lipid-lowering therapy, and body mass index (P < 0.05). RCS analysis demonstrated a linear increase in the risk of MASLD with higher UAR levels (P for nonlinear = 0.319). ROC curve analysis indicated that UAR provided good diagnostic performance for MASLD (AUC:0.777, 95% CI: 0.749- 0.805), comparable to TAR (AUC difference: -0.003, 95% CI: -0.033-0.026, P = 0.818) and superior to UHR (AUC difference: 0.043, 95% CI: 0.019-0.067, P < 0.001) and THR (AUC difference: 0.035, 95% CI: 0.019-0.067, P = 0.047).Conclusion: UAR was independently associated with MASLD and demonstrated significant diagnostic value, indicating that UAR could be a cost-effective biomarker to help identify high-risk individuals for MASLD.